Dr. Steven I. Park, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, Davis School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 71
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of California, Davis School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NC license 2009-01662 -
Hematology & Oncology Physician
NC license 2009-01662 -
Internal Medicine Physician
NC license 2009-01662
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Carolinas Medical Center/behav Health Charlotte, NC
- Carolinas Medical Center-Northeast Concord, NC
Medical groups
- The Charlotte-Mecklenburg Hospital Authority (601 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 71
- Services billed
- 166
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 62 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 36 | 20 |
| Established patient office or other outpatient visit, 20-29 minutes | 23 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Concord, NC | 24 |
| Calquence (acalabrutinib maleate) | 21 |
| Brukinsa (zanubrutinib) | 21 |
| Revlimid (lenalidomide) | 11 |
| Prednisone Other prescribers in Concord, NC | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $4,119 in total to this clinician.
| Ipsen Bioscience Inc. | $4,100 |
|---|---|
| Adaptive Biotechnologies Corporation | $18.97 |
| Consulting Fee | $4,100 |
|---|---|
| Food and Beverage | $18.97 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Bioscience Inc. Apr 16, 2025 | Consulting Fee | $4,100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $17,279 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.